Main Article Content
Limb-Girdle muscular dystrophy (LGMD) is a group of inherited disorders that lead to muscle weakness and skeletal muscle wasting involving the muscles around the hips and shoulders. This can cause a gait disturbance, difficulty running or even a complete loss of the ability to walk. The appearance of the disorder, the course and the muscles affected are variable between the different subtypes of the disease. Typically, patients with type 2C Limb-Girdle dystrophy (LGMD2C) start having symptoms early in infancy and lose their ability to walk around the age of 12. Others have less symptomatology and have late expression in adulthood. This disorder can affect the heart muscle in some patients. They can also have osteoarticular and vertebral deformations. The prognosis depends on the muscles often affected by respiratory failure.LGMD2C is caused by a pathogenic mutation in the SGCG gene. We report the case of a 13-year-old child, with a notion of femoral fracture at the age of 5 years and first degree consanguinity in the parents, no similar case in the family, and who presents since 3 years difficulty walking Clinical examination: walking, positive sign of Gowers, scapula alta, enlarged calves. On the biological level: CPK 6380, LDH 482, PAL 219, ASAT 68, ALAT 103. The electromyogram shows a slowing of the motor conduction speed of the external popliteal sciatic nerve with a slight loss of amplitude. Muscle biopsy objective a discreet dystrophic formula with a total absence of expression of gamma sarcoglycans and proteins of the muscle membrane. Gamma glycanopathy is genetically confirmed by the mutation of the δ-SG gene. A cardiac ultrasound was without abnormality.
Sandonà D, Betto R. Sarcoglycanopathies: Molecular pathogenesis and therapeutic prospects. Expert Rev Mol Med. 2009; 11:e28.
Ben Jelloun-Dellagi S, Chaffey P, Hentati F, Ben Hamida C, Tome F, Colin H, Dellagi K, Kaplan JC, Fardeau M, Ben Hamida M. Presence of normal dystrophin in Tunisian severe childhood autosomal recessive muscular dystrophy. Neurology. 1990; 40:1903.
Pogue R, Anderson LV, Pyle A, Sewry C, Pollitt C, Johnson MA, Davison K, Moss JA, Mercuri E, Muntoni F, Bushby KM. Strategy for mutation analysis in the autosomal recessive limb-girdle muscular dystrophies. Neuromuscul Disord. 2001; 11:80-7.
Moreira ES, Vainzof M, Suzuki OT, Pavanello RC, Zatz M, Passos- Bueno MR. Genotype-phenotype correlations in 35 Brazilian families with sarcoglycanopathies including the description of three novel mutations. J Med Genet. 2003;40:E12.
Gulati S, Leekha S, Sharma MC, Kalra V. Gamma-sarcoglycanopathy. Indian Pediatr. 2003;40:1077-81.
Azibi K, Bachner L, Beckmann J S, Matsumura K, Hamouda E, Chaouch M, Chaouch A, Ait-Ouarab R, Vignal A, Weissenbach J. Severe childhood autosomal recessive muscular dystrophy with the deficiency of the 50 kDa dystrophin-associated glycoprotein maps to chromosome 13q12. Hum Molec Genet. 1993;2:1423-28.
El Kerch F, Sefiani A, Azibi K, Boutaleb N, Yahyaoui M, Bentahila A, Vinet MC, Leturcq F, Bachner L, Beckmann J, et al. Linkage analysis of families with severe childhood autosomal recessive muscular dystrophy in Morocco indicates genetic homogeneity of the disease in North Africa. J Med Genet. 1994;31:342-3.
Klinge L, Dekomien G, Aboumousa A, Charlton R, Epplen JT, Barresi R, Bushby K, Straub V. Sarcoglycanopathies: Can muscle immunoanalysis predict the genotype? Neuromuscul Disord. 2008; 18:934-41.
Trabelsi M, Kavian N, Daoud F, Commere V, Deburgrave N, Beugnet C, Llense S, Barbot JC, Vasson A, Kaplan JC, Leturcq F, Chelly J. Revised spectrum of mutations in sarcoglycanopathies. Eur J Hum Genet. 2008;16:793-803.
Ferreira AF, Carvalho MS, Resende MB, Wakamatsu A, Reed UC, Marie SK. Phenotypic and immunohistochemical characterization of sarcoglycanopathies. Clinics (Sao Paulo). 2011;66:1713-19.
Jung D, Leturcq F, Sunada Y, Duclos F, Tome FMS, Moomaw C, Merlini L, Azibi K, Chaouch M, Slaughter C, Fardeau M, Kaplan JC, Campbell KP. Absence of gamma-sarcoglycan (35 DAG) in autosomal recessive muscular dystrophy linked to chromosome 13q12. FEBS Lett. 1996;381:15-20.
Kefi M, Amouri R, Driss A, Ben Hamida C, Ben Hamida M, Kunkel LM, Hentati F. Phenotype and sarcoglycan expression in Tunisian LGMD 2C patients sharing the same del521-T mutation.Neuromuscul Disord. 2003;13:779-87.
Navarro C, Teijeira S. Neuromuscular disorders in the Gypsy ethnic group: A short review. Acta Myol. 2003;22:11-14.
McNally EM, Passos-Bueno MR, Bo¨nnemann CG, et al. Mild and severe muscular dystrophy caused by a single gamma sarcoglycan mutation. Am J Hum Genet. 1996;59:1040–1047.
Jaouad IC, Elalaoui SC, Sbiti A, et al. Consanguineous Marriages in Morocco and the consequence for the incidence of autosomal recessive disorders. J Biosoc Sci. 2009;41:575–581.
Fatiha El Kerch, Ilham Ratbi, Aziza Sbiti, Fatima-Zohra Laarabi, Amina Barkat, Abdelaziz Sefiani. Carrier Frequency of the c.525delT Mutation in the SGCG Gene and Estimated Prevalence of Limb Girdle Muscular Dystrophy Type 2C Among the Moroccan Population. Genetic testing and molecular biomarkers. 2014;18(4).
Noguchi S, McNally EM, Ben Othmane K, et al. Mutations in the dystrophin-associated protein y-sarcoglycan in chromosome 13 muscular dystrophy. Science. 1995;270:819–822.
Prevalence des maladies rares: Donnees bibliographiques. Les Cahiers d’Orphanet, Numero 1 ; 2011.